Fig. 8: Treatment with anti-IL-1R1 antibody ameliorates BM fibrosis in homozygous Jak2V617F mouse model.

a A scheme on the experimental design is depicted. b Peripheral blood WBC, neutrophil (NE), platelet (PLT) and red blood cell (RBC) counts were assessed at 3 and 6 weeks after the treatment (n = 7 mice per group). c, d Frequencies of Gr1⁺Mac1⁺ and CD41⁺ cells in the BM of Jak2^VF/F mice treated with PBS and IL-1R1 Ab (n = 7 mice per group). e, f Frequencies of Gr1⁺Mac1⁺ and CD41⁺ cells in the spleens (SPL) of Jak2^VF/VF mice treated with PBS and IL-1R1 Ab (n = 7 mice per group). g Frequencies of LSK, LT-HSC and ST-HSC in the BM of Jak2^VF/VF mice treated with PBS and IL-1R1 Ab (n = 7 mice per group). Results are shown in bar graphs as mean ± SEM. h Frequencies of LK, CMP, GMP and MEP in the BM of Jak2^VF/F mice treated with PBS and IL-1R1 Ab (n = 7 mice per group). i, j CFU-GM (i) and CFU-Mk (j) colonies in the BM of Jak2^VF/VF mice treated with PBS and IL-1R1 Ab (n = 7 mice per group). k Spleen size/weight in Jak2^VF/VF mice treated with vehicle (PBS) and IL-1R1 Ab are shown (n = 5 mice per group). l Representative images of the hematoxylin and eosin (H&E) and reticulin stained BM sections from Jak2^VF/F mice treated with PBS or IL-1R1 Ab. Scale bars, 20 μm. Histological grade of BM fibrosis is shown in bar graphs as mean ± SEM (n = 5 mice per group). Statistical significances were determined using multiple unpaired two-tailed t-tests. Source data are provided as a Source Data file.